- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
After having successfully carried out the first joint feasibility studies on the application of the LBL Technology for the improved delivery of pharmaceutical substances, Midas Pharma and Capsulution have set up the framework for long-term cooperation.
The object of the cooperation contract, signed in June, is the joint implementation of projects for the development of improved pharmaceutical products for the pharmaceutical industry. The framework of the contract ensures the Midas Pharma GmbH access to the innovative technology of the Berlin-based start up company and provides in exchange their expertise in the downstream areas of the pharmaceutical value chain. In this way, Capsulution will be able to offer their pharmaceutical companies additional services in all issues concerning the procurement of pharmaceutical substances, pharmaceutical contract manufacturing, international license projects or the creation of registration dossiers.
"Midas Pharma with its worldwide subsidiary representations is present on the most important pharmaceutical markets and opens up for us a new range of market opportunities," explains Alexander Herrmann, CFO of Capsulution. "We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner from the pharmaceutical industry," adds Hermann. For Capsulution, the partnership offers the opportunity to strengthen the focus by widening the spectrum of services. "Our key competence is as always the development of innovative drug delivery systems for a targeted and secure application of the active pharmaceutical substance based upon our worldwide patented LBL Technology®," states Herrmann. "On the other hand, so-called standard pharmaceutical services should be provided by a growing network of partners," Hermann concludes.
For Midas also, the cooperation with Capsulation represents an important step forward: "The cooperation with Capsulution is a major contribution towards expanding our current range of products and services," explains Marcus Stumpf, managing director of Midas. The wide-ranging application of Capsulution's toolbox-like formulation platform delivers promising solution approaches in the development of various pharmaceutical products. In this sense, the cooperation of both companies is a win-win situation for Midas and Capsulution.
About Capsulution NanoScience AG
Capsulution NanoScience AG is a leading company in the field of tailor-made drug-delivery systems and other innovative life science products on the basis of so-called nanocapsules. These nanocapsules are manufactured on the basis of the worldwide patent protected LBL Technology®. Due to their minute size and high level of functionability as well as their extremely reproducible manufacture, the capsules can be used in a diverse number of applications. The nano- and microcapsules can be manufactured in any desired size, according to application and endowed with practically any biochemical, electric, optical and magnetic properties.
About Midas Pharma GmbH
Midas Pharma is an independent marketing and sales company, active in various areas of the pharmaceutical value chain. Midas Pharma supports customers and manufacturing partners in all issues concerning pharmaceutical substances, biosimilar products, pharmaceutical contract syntheses, pharmaceutical contract manufacturing, international licensing products and registration dossiers.
On the German market, Midas Pharma represents more than 30 leading manufacturers of pharmaceutical raw materials, standardized extracts, plant and animal-based pharmaceutical substances as well as interim production for pharmaceutical syntheses. Since its founding in 1988, research-oriented pharmaceutical companies as well as customers from the field of generic products have been relying on the services of Midas.
For more information, please click here
Capsulution NanoScience AG
Capsulution NanoScience AG
Telefon: +49 (30) 6706919-129
Fax: +49 (30) 6706919-101
Chief Financial Officer (CFO)
Dr. Sigrid Saaler-Reinhardt
Midas Pharma GmbH
Telefon: +49 (6132) 990-0
Fax: +49 (6132) 990-694
Head of R&D / Intellectual Property Management
Copyright © Capsulution NanoScience AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEI’s QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Region’s Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016